Mechanisms of the contractile effects of 2,3-butanedione-monoxime in the mammalian heart.
We studied the mechanisms of action of a negative inotropic compound, 2,3-butanedione-monoxime (BDM), which has been suggested to be a cardioprotective agent. In guinea-pig papillary muscles the negative inotropic effect of BDM start at 100 mumol/l amounting to 18.32 +/- 2.09% of predrug value at 10 mmol/l without any effects on time parameters (n = 12, each). 30 mmol/l BDM totally abolished force of contraction; this effect was reversible after washout. In the presence of the phosphatase-inhibitor cantharidin (30 mumol/l) the concentration response curve on force of contraction was shifted to higher concentrations of BDM. 100 mmol/l BDM decreased the phosphorylation state of the inhibitory subunit of troponin (TnI) and phospholamban (PLB) in [32P]-labeled guinea-pig ventricular myocytes to 76.5 +/- 4.7% and 49.7 +/- 4.2%, respectively (n = 7). Furthermore, BDM enhanced the activity of phosphorylase phosphatases in guinea-pig ventricular homogenates amounting to a stimulation to 203.5 +/- 10.4% at 100 mmol/l whereas type 1 phosphorylase phosphatase activity increased only by 24.5% (n = 5). PLB phosphatase activity was enhanced to 155.9 +/- 11.7% by 100 mmol/l BDM (n = 5). It is concluded that the effects of BDM on contractile parameters are accompanied by decreased phosphorylation of the cardiac regulatory proteins TnI and PLB which could in part be due to activation of type 1 or 2A phosphatase activity. Hence, it is suggested that BDM affects the phosphorylation state of TnI and PLB not directly, but via activation of their phosphatases.
Zimmermann
N
N
Klinik für Thorax- und Kardiovaskuläre Chirurgie, Heinrich Heine-Universität, Düsseldorf, Germany.
Boknik
P
P
Gams
E
E
Gsell
S
S
Jones
L R
LR
Maas
R
R
Neumann
J
J
Scholz
H
H
D000818:Animals; D002135:Calcium-Binding Proteins / Q000378:metabolism; D003931:Diacetyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D066298:In Vitro Techniques; D009200:Myocardial Contraction / Q000187:drug effects* / Q000502:physiology; D009206:Myocardium / Q000166:cytology / Q000201:enzymology / Q000378:metabolism; D010749:Phosphoprotein Phosphatases / Q000187:drug effects / Q000378:metabolism; D010765:Phosphorylase Phosphatase / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D014336:Troponin / Q000378:metabolism; D000099211:Phospholamban
D002135:Calcium-Binding Proteins; D003931:Diacetyl; D010749:Phosphoprotein Phosphatases; D010765:Phosphorylase Phosphatase; D014336:Troponin; D000099211:Phospholamban; C004717:diacetylmonoxime; C057399:phospholamban phosphatase